Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Digestive DisorderOrphan Drug

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1542790

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1542790

Crohn's Disease (CD) Therapy

PUBLISHED:
PAGES: 142 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Crohn's Disease (CD) Therapy Market to Reach US$17.7 Billion by 2030

The global market for Crohn's Disease (CD) Therapy estimated at US$12.7 Billion in the year 2023, is expected to reach US$17.7 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2023-2030. Anti-TNF Biologics, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$7.4 Billion by the end of the analysis period. Growth in the Aminosalicyates segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.5 Billion While China is Forecast to Grow at 4.5% CAGR

The Crohn's Disease (CD) Therapy market in the U.S. is estimated at US$3.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 4.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.8% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Crohn's Disease (CD) Therapy Market - Key Trends and Drivers Summarized

Combating Crohn's Disease: What's New in CD Therapy?

Crohn's Disease (CD) therapy has evolved significantly, moving beyond traditional symptom management to more targeted approaches aimed at modifying the disease course and improving quality of life. Advances in medical research have led to the development of biologic therapies that specifically target proteins and pathways involved in inflammation. These include TNF inhibitors, integrin inhibitors, and interleukin inhibitors, which have shown efficacy in reducing symptoms and achieving remission in many patients. Additionally, the use of immunomodulators in combination with biologics has become a common strategy to enhance therapeutic outcomes and minimize side effects.

How Are Emerging Therapies Transforming Treatment Paradigms in CD?

Emerging therapies in CD focus on new targets within the immune system and the gut microbiome, which play crucial roles in the pathogenesis of the disease. JAK inhibitors, a newer class of small molecule drugs, have shown promise in treating moderate to severe CD by blocking key enzymes involved in the inflammatory process. Moreover, fecal microbiota transplantation (FMT) and the use of probiotics are being explored to restore intestinal microbiome balance, offering a novel approach to therapy that could potentially lead to better disease management and remission rates.

What Challenges Persist in the Management of Crohn's Disease?

Despite advancements, managing CD remains challenging due to its complex nature and variability in symptoms and treatment responses among patients. One of the biggest challenges is the chronic relapsing-remitting pattern of the disease, which can complicate long-term management strategies and affect patient adherence to treatment. Additionally, the risk of complications such as strictures, fistulas, and colorectal cancer requires ongoing monitoring and sometimes surgical intervention, adding to the disease burden. Furthermore, the cost of newer therapies, particularly biologics, can be prohibitively high, limiting access for many patients.

What Drives the Growth in the CD Therapy Market?

The growth in the CD therapy market is driven by several factors. An increasing incidence of inflammatory bowel diseases globally and greater awareness of CD are key factors contributing to the growing demand for effective treatments. Advances in diagnostic techniques allow for earlier and more accurate diagnosis, facilitating timely treatment initiation. The development of novel therapeutics that offer improved efficacy and safety profiles also stimulates market expansion. Additionally, rising healthcare expenditure and better healthcare infrastructure, particularly in developing countries, enhance access to advanced therapies, further driving market growth.

Select Competitors (Total 46 Featured) -

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Celltrion Healthcare Co., Ltd.
  • ChemoCentryx, Inc.
  • Ferring Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Takeda Pharmaceutical Co., Ltd.
  • UCB SA
Show more
Product Code: MCP11374

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Crohn's Disease (CD) Therapy - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Crohn's Disease Drives Demand for Effective Therapies
    • Growing Awareness and Better Diagnostic Techniques Bolster Early Treatment Adoption
    • Expansion of Healthcare Infrastructure Supports Accessibility to Advanced CD Therapies
    • Emerging Markets Exhibit Increased Demand Due to Rising Healthcare Spending
    • Growing Demand for Non-Surgical Interventions Bolsters Non-Invasive Therapy Development
    • Shift Toward Combination Therapies Offers Comprehensive Disease Management
    • Nutritional Research Influences Adjunct Therapies in CD Treatment Regimens
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Crohn's Disease (CD) Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Crohn's Disease (CD) Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Aminosalicyates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Aminosalicyates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Aminosalicyates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Immunomodulators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Anti-TNF Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Anti-TNF Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Anti-TNF Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Anti-Integrin Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Anti-Integrin Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Anti-Integrin Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 22: World Crohn's Disease (CD) Therapy Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Crohn's Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • JAPAN
    • Crohn's Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • CHINA
    • Crohn's Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: China Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: China 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • EUROPE
    • Crohn's Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Crohn's Disease (CD) Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Crohn's Disease (CD) Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Europe 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • FRANCE
    • Crohn's Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 41: France Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: France Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: France 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • GERMANY
    • Crohn's Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Germany Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Germany 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 47: Italy Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Italy Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Italy 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Crohn's Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: UK Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: UK 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Rest of Europe 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Crohn's Disease (CD) Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 59: Rest of World Recent Past, Current & Future Analysis for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Rest of World Historic Review for Crohn's Disease (CD) Therapy by Segment - Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Rest of World 16-Year Perspective for Crohn's Disease (CD) Therapy by Segment - Percentage Breakdown of Value Sales for Anti-TNF Biologics, Aminosalicyates, Immunomodulators, Anti-Integrin Biologics, Biosimilars and Other Segments for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!